RWD172 Healthcare Utilization and Costs Among Patients With Episodic Migraine Initiating Galcanezumab Versus Rimegepant for Migraine Prevention in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2469
https://www.valueinhealthjournal.com/article/S1098-3015(24)02683-4/fulltext
Title :
RWD172 Healthcare Utilization and Costs Among Patients With Episodic Migraine Initiating Galcanezumab Versus Rimegepant for Migraine Prevention in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02683-4&doi=10.1016/j.jval.2024.03.2469
First page :
Section Title :
Open access? :
No
Section Order :
11478